🚀 VC round data is live in beta, check it out!
Legend Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Legend Biotech and similar public comparables like Hikma Pharmaceuticals, Amoytop Biotech, Indivior Pharmaceuticals, NewAmsterdam Pharma and more.
Legend Biotech Overview
About Legend Biotech
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Founded
2015
HQ
Employees
2.6K
Website
Sectors
Financials (LTM)
EV
$3B
Legend Biotech Financials
Legend Biotech reported last 12-month revenue of $1B and negative EBITDA of ($77M).
In the same LTM period, Legend Biotech generated $707M in gross profit, ($77M) in EBITDA losses, and had net loss of ($190M).
Revenue (LTM)
Legend Biotech P&L
In the most recent fiscal year, Legend Biotech reported revenue of $1B and EBITDA of ($163M).
Legend Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $707M | XXX | $621M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | ($77M) | XXX | ($163M) | XXX | XXX | XXX |
| EBITDA Margin | (7%) | XXX | (16%) | XXX | XXX | XXX |
| EBIT Margin | (7%) | XXX | (13%) | XXX | XXX | XXX |
| Net Profit | ($190M) | XXX | ($297M) | XXX | XXX | XXX |
| Net Margin | (17%) | XXX | (29%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Legend Biotech Stock Performance
Legend Biotech has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
Legend Biotech's stock price is $21.15.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | 0.3% | XXX | XXX | XXX | $-1.60 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLegend Biotech Valuation Multiples
Legend Biotech trades at 2.9x EV/Revenue multiple, and (43.9x) EV/EBITDA.
EV / Revenue (LTM)
Legend Biotech Financial Valuation Multiples
As of April 18, 2026, Legend Biotech has market cap of $4B and EV of $3B.
Equity research analysts estimate Legend Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Legend Biotech has a P/E ratio of (20.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | (43.9x) | XXX | (20.7x) | XXX | XXX | XXX |
| EV/EBIT | (44.9x) | XXX | (24.8x) | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | 5.4x | XXX | XXX | XXX |
| P/E | (20.6x) | XXX | (13.2x) | XXX | XXX | XXX |
| EV/FCF | (27.9x) | XXX | (26.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Legend Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Legend Biotech Margins & Growth Rates
Legend Biotech's revenue in the last 12 month grew by 35%.
Legend Biotech's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Legend Biotech's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Legend Biotech's rule of X is 107% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Legend Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 35% | XXX | 39% | XXX | XXX | XXX |
| EBITDA Margin | (7%) | XXX | (16%) | XXX | XXX | XXX |
| EBITDA Growth | (356%) | XXX | (178%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 48% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 107% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | 13% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 36% | XXX | 40% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 74% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Legend Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Legend Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Hikma Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Amoytop Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Indivior Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| NewAmsterdam Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Zelgen Biopharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Legend Biotech M&A Activity
Legend Biotech acquired XXX companies to date.
Last acquisition by Legend Biotech was on XXXXXXXX, XXXXX. Legend Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Legend Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLegend Biotech Investment Activity
Legend Biotech invested in XXX companies to date.
Legend Biotech made its latest investment on XXXXXXXX, XXXXX. Legend Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Legend Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Legend Biotech
| When was Legend Biotech founded? | Legend Biotech was founded in 2015. |
| Where is Legend Biotech headquartered? | Legend Biotech is headquartered in United States. |
| How many employees does Legend Biotech have? | As of today, Legend Biotech has over 2K employees. |
| Who is the CEO of Legend Biotech? | Legend Biotech's CEO is Ying Huang. |
| Is Legend Biotech publicly listed? | Yes, Legend Biotech is a public company listed on Nasdaq. |
| What is the stock symbol of Legend Biotech? | Legend Biotech trades under LEGN ticker. |
| When did Legend Biotech go public? | Legend Biotech went public in 2020. |
| Who are competitors of Legend Biotech? | Legend Biotech main competitors are Hikma Pharmaceuticals, Amoytop Biotech, Indivior Pharmaceuticals, NewAmsterdam Pharma. |
| What is the current market cap of Legend Biotech? | Legend Biotech's current market cap is $4B. |
| What is the current revenue of Legend Biotech? | Legend Biotech's last 12 months revenue is $1B. |
| What is the current revenue growth of Legend Biotech? | Legend Biotech revenue growth (NTM/LTM) is 35%. |
| What is the current EV/Revenue multiple of Legend Biotech? | Current revenue multiple of Legend Biotech is 2.9x. |
| Is Legend Biotech profitable? | No, Legend Biotech is not profitable. |
| What is the current EBITDA of Legend Biotech? | Legend Biotech has negative EBITDA and is not profitable. |
| What is Legend Biotech's EBITDA margin? | Legend Biotech's last 12 months EBITDA margin is (7%). |
| What is the current EV/EBITDA multiple of Legend Biotech? | Current EBITDA multiple of Legend Biotech is (43.9x). |
| What is the current FCF of Legend Biotech? | Legend Biotech's last 12 months FCF is ($121M). |
| What is Legend Biotech's FCF margin? | Legend Biotech's last 12 months FCF margin is (11%). |
| What is the current EV/FCF multiple of Legend Biotech? | Current FCF multiple of Legend Biotech is (27.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.